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How Should Oxygen 
Supplementation Be Guided by Pulse 
Oximetry in Children: Do We Know 
the Level?
Ross Langley and Steve Cunningham*
Department of Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK
Supplemental oxygen is one of the most commonly prescribed therapies to children in 
hospital, but one of the least studied therapeutics. This review considers oxygen from a 
range of perspectives; discovery and early use; estimation of oxygenation in the human 
body—both clinically and by medical device; the effects of illness on oxygen utilization; 
the cellular consequences of low oxygen; and finally, how clinical studies currently inform 
our approach to targeting supplementing oxygen in those with lower than normal oxygen 
saturation.
Keywords: oxygen, lower respiratory tract infection, oxygen saturation, hypoxia, hypoxemia
Oxygen really is the elixir of life. It is vital for ATP production at the mitochondrial powerhouse of 
cellular function, a lack of oxygen spells cell injury and death. No wonder clinicians are so cautious 
of low oxygen states. But how cautious do we need to be? Is our physiological system able to manage 
low oxygen challenges? And what should be considered low from a clinical perspective?
This review will consider our understanding of oxygen: its history, physiological principles, 
monitoring in our bodies, the effects of low oxygen at a cellular level, and how much clinical studies 
inform our understanding of risks and benefits of supplementing oxygen.
OXYGEN—A BRIEF HISTORY
In the late 18th century, the Swedish pharmacist Karl Scheele and the English theologian– chemist 
Joseph Priestley did a series of independent combustion experiments with mercuric oxide and 
potassium nitrate inadvertently discovering a new “air” (Experiments and Observations on Different 
Kinds of Air, Vol. 1–6, 1775, London). After refinements by Antoine Lavoisier in 1778, the gas was 
named oxyge’ne (meaning acid former). The first recorded medicinal use was 5 years later by the 
French physician Caillens who treated a young woman suffering from tuberculosis.
The medicinal use of oxygen became popular by the end of the 18th century supported by the 
“Pneumatic Institution.” Despite some medical studies throughout the 19th century (1) with advanced 
understanding of physical and chemical properties of oxygen (the Fick Principle in particular), it 
was not until 1917 when the Scottish physician/physiologist John Scott Haldane published a seminal 
paper on the proposed therapeutic administration of oxygen that sparked a revolution for the use 
of oxygen in medicine (2): continuous oxygen delivery was more beneficial than intermittent use. 
Though it would not be until the 1960s, his theory was proved correct (3). Recent novel approaches 
to oxygen delivery include high flow devices and non-invasive ventilation strategies.
FIGURE 1 | Oxygen in children – what level. Oxyhemoglobin dissociation 
curve.
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PHYSIOLOGICAL PRINCIPLES OF 
OXYGEN
Oxygen is carried in the blood principally bound to hemoglobin 
(Hb), but also dissolved within plasma. The relationship between 
oxygen saturation and blood oxygen content can be estimated 
with reference to the oxygen dissociation curve (Figure 1). This 
relationship is stable during health, but can be affected by a 
number of factors that influence the ease (or affinity) with which 
oxygen is bound to and released from Hb, including temperature, 
partial pressure of carbon dioxide, 2,3-diphosphoglycerate, and 
pH. A right shift makes it more difficult for oxygen to bind to Hb, 
but easier for it to be released at the tissues. A left shift has the 
opposite, easier binding but less readily released. As Hb becomes 
fully saturated, additional oxygen must be dissolved within 
plasma, which has a limited capacity under normal circumstances 
(but can be enhanced by supplementing oxygen above FiO2 0.21). 
Decrease in pH/increased H+ ion shifts the curve to right and to 
the left with alkalosis. This is known as the Bohr effect. Carbon 
dioxide affects the curve in two ways: first, it influences intracellu-
lar pH (the Bohr effect), and second, CO2 accumulation generates 
high-level carb-amino compounds causing a right shift. 2,3-DPG 
is an organophosphate, generated in erythrocytes during glycoly-
sis. The production of 2,3-DPG increases with respect to reduced 
peripheral tissue oxygen. High levels of 2,3-DPG shift the curve 
to the right. Low levels of 2,3-DPG is seen in states such as septic 
shock and hypophosphataemia and cause left shift. Hyperthermia 
causes a right shift, while hypothermia causes a left shift. Carbon 
monoxide binds Hb 240 times more readily than oxygen, and 
therefore interferes with Hb’s acquisition of oxygen. It lowers the 
potential for Hb to bind to oxygen and shifts the curve to the 
left via formation of carboxyhaemaglobin. In the context of an 
increased level of carbon monoxide, a person can suffer from 
severe tissue hypoxia while maintaining normoxaemia/normal 
PaO2 (4). Methemoglobinemia (a form of abnormal Hb) causes 
a left shift in the curve. Fetal hemoglobin (HbF) is structurally 
different from adult Hb. The fetal dissociation curve is shifted to 
the left relative to adults. Typically, the fetal arterial partial pres-
sure of oxygen is low and hence the left shift enhances placental 
uptake of oxygen.
Normal values of oxygen saturation have been reported widely 
(5, 6) and at sea level (101 kPa/760 mmHg) oxygen saturation 
is within the normal range when reading between 94–100%. An 
oxygen saturation below 94% is hypoxemia. Oxygen saturations 
are lower in those living at altitude (estimated at a reduction of 5% 
per 1000 m altitude) (7). Once above an altitude of 6500 m, oxygen 
saturation stabilize at about 60–65% and do not drop further due 
to an increase in ventilation and the subsequent respiratory alka-
losis shifting the oxyhemoglobin dissociation curve to the left (8).
ASSESSING OXYGEN
Clinical Determination of  
Low Oxygen States
Historically, and today in resource poor regions, low oxygen sta-
tus is determined clinically by identifying cyanosis – a dark blue/
purple discoloration of the skin or mucous membranes (typically 
the tongue or inner lip). Cyanosis is one of the earliest and critical 
signs a medical student will be taught (9). It is one of the cardinal 
signs of severe illness, and failure to recognize cyanosis can 
appropriately lead to increased patient morbidity (10). Cyanosis 
is therefore considered a critical test of clinical ability to be able 
to appropriately identify and, if present, treat with supplemental 
oxygen. It is, however, a difficult clinical sign to elicit visually and 
recognition can be complicated by a number of factors including 
room lighting, skin pigmentation, and anemia.
For most clinicians, the point at which they are confidently 
able to discriminate someone as demonstrating cyanosis equates 
to approximately 85% oxygen saturation. However, detection of 
clinical cyanosis in respiratory illness varies appreciably from cli-
nician to clinician (11), and identifying hypoxemia is significantly 
improved by availability of oxygen saturation measurement (12).
Determination of Low Oxygen Using 
Medical Device
Arterial blood sampling for determination of arterial oxygena-
tion is painful and invasive, and as a consequence of limited use in 
pediatrics outside intensive care. As a consequence, non-invasive 
surrogates for arterial oxygen, i.e., pulse oximetry, are extremely 
helpful in estimating oxygen saturation. Oxygen saturation 
monitoring is a relatively new technology, and although ubiqui-
tous in developed healthcare settings, it is not available to the 
majority of people who require an estimate of oxygenation during 
ill health in developing healthcare settings (13). The principle 
of pulse oximetry is based on the red and infrared (IR) light 
absorption of oxygenated and deoxygenated Hb. Oxygenated 
Hb absorbs more IR light (wavelength 850–1000 nm) whereas 
deoxygenated/reduced Hb absorbs more red light (wave length 
600–750 nm). Red (R) and IR light are emitted through an area 
of skin with good blood flow. A photodetector is sited opposite to 
the emitter and receives the wavelength of light passing through 
TABLE 1 | Oxygen in children – what level.
Organ % of Cardiac 
output
Blood flow  
(ml/min)
Oxygen uptake  
(ml/min)
Brain 14 840 52
Heart 5 300 34
Splanchnic bed 28 1,680 83
Kidney 23 1,380 19
Skeletal muscle 16 960 57
Skin 8 480 12
Adapted from Ref. (18).
FIGURE 2 | Oxygen in children what level. Adapted from Gutierrez and 
Theodorou (15).
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the measuring site. Light is increasingly absorbed during a pulse 
“wave” and more accurately reflects arterial blood oxygen levels. 
The R/IR ratio is calculated following photodetection. Typically, 
an R/IR ratio of 0.5 equates to approximately 100% SpO2, a ratio 
of 1.0 equates to approximately 82% SpO2, while a ratio of 2.0 
equates to 0% SpO2. Measured values will be inaccurate if there is 
movement or extraneous light (particularly with incorrect sized 
clip in children) or if nail polish is in  situ. Skin pigmentation 
should not affect accuracy. Oxygen saturation readings <70% are 
generally considered unreliable, as the monitors algorithms are 
imprecise below this level. Likewise, to improve accuracy, beat to 
beat measurements are not generally accepted due to artifactual 
influences; therefore, the SpO2 value represents an average over-
time (a period typically of 10–15 s).
The introduction of pulse oximetry in a widespread manner in 
the 1980s and 1990s provided a clearly presented, precise number 
that staff find authoritatively acceptable. The step difference from 
our previous understanding of clinically detected cyanosis (85% 
oxygen saturation) to achieving normoxia (94% oxygen satura-
tion) has provided a whole new level of clinical concern – what 
exactly does an oxygen saturation in the range 85–94% mean 
in the context of disease. Is it necessary to have normal oxygen 
saturation during illness?
Before the widespread use of oxygen saturation monitoring, 
supplemental oxygen was used either blindly (at a set level for 
a set time) or to relieve clinical cyanosis (i.e., oxygen saturation 
below c85%). The widespread availability of supplemental oxygen 
and precise, reliable, ubiquitous methods of estimating arterial 
oxygen provide clinicians with a capability for meticulousness 
that requires supporting evidence for benefits and harm.
WHAT IS LOW OXYGEN?
Hypoxia is low tissue oxygen associated with tissue injury, 
whereas hypoxemia is low blood oxygen levels that may or may 
not be associated with hypoxia. The level of oxygen carried in the 
blood depends on the amount of oxygen bound to Hb and, to a 
lesser extent, dissolved in blood. In healthy humans breathing 
room air (21% oxygen) at sea level (101 kPa/760 mmHg), the 
partial pressure of arterial blood oxygen will be in the range 
11–13 kPa (75–100 mmHg). At this level, intracellular oxygen is 
2.7 kPa (20 mmHg) and mitochondrial oxygen is above 1.3 kPa 
(9.7 mmHg).
Tissues cannot store oxygen and therefore must be supplied 
with a constant and steady supply. The global amount of oxygen 
delivery per minute is termed DO2. Reduction in DO2 is associ-
ated with reduced renal blood flow (with consequent reduction 
in urine output), lethargy, metabolic acidosis, and (if measured) 
a lower venous oxygen saturation (14). Delivery at a tissue 
level may be further compromised in those who are affected by 
anemia, hypovolemia, poor cardiac output, or edema of tissues. 
The global amount of oxygen consumed each minute is termed 
VO2. Global oxygen consumption (VO2) at a cellular level is 
increased by pyrexia, physical activity (increased respiratory rate 
or seizures), catabolic states, and pain, whereas VO2 is reduced by 
sedation, muscle paralysis, assisted ventilation and hypothermia. 
In normal health, oxygen consumption is supply independent; 
however, with illness, increased extraction and reduced delivery 
can compromise the DO2 critical point leading to supply failure 
and hypoxia (Figure 2).
Although global oxygen delivery and consumption can be 
determined, the ability to identify specific dynamic organ level 
risk is limited in day to day practice. Different organs and tissue 
groups have varied blood flow and oxygen uptake each minute, 
receiving varied amounts of cardiac output (Table 1). In hypoxic 
states, preferential shunting of blood away from tissues with low 
oxygen demand (skin, intestinal tract) help to maintain oxygen 
delivery to vital organs such as heart and brain which have high 
oxygen extraction rates and a poorer ability to tolerate low oxy-
gen delivery. At a cellular level, reduced oxygen carried within 
capillaries reduces intracellular and consequently mitochondrial 
PaO2. Critical mitochondrial levels of oxygen lie in the range 
0.01–0.10 kPa (16). Tissues particularly sensitive to low oxygen 
supply are renal tubular cells, cardiomyocytes, and neurons (17).
EFFECTS OF HYPOXIA ON  
CELLULAR LEVEL
Cells are vulnerable to both excessive and inadequate levels of 
oxygen. Protection from hypoxic/hyperoxic insults is achieved by 
complex homeostatic responses which influence cardiovascular, 
respiratory, and hematological parameters. The influence of 
FIGURE 3 | Regulation of hypoxia-inducible factor (HIF)-1 oxygen in children – what level. Regulation of HIF-1 adapted from Imtiyaz and Simon (19) and 
Semenza (20). HIF transcription factors are heterodimers consisting of an oxygen-regulated alpha chain bound to the constitutive beta subunit (aryl hydrocarbon 
receptor nuclear translocator). Under normoxic conditions, the alpha chain hydroxylated by the HIF prolyl hydroxylases leading to recognition by the von Hippel–
Lindau (VHL) E3 ubiquitin ligase complex VHL which recruits elongins B and C, Cullin 2, and RBX1 (R) to constitute a functional E3 ubiquitin-protein ligase complex. 
Polyubiquitylation occurs and the alpha chain is degraded by the proteasome. Under hypoxic conditions, the HIF alpha chains are maintained and target gene 
transcription is enhanced. HIF-1 dimerizes and escapes prolyl hydroxylation, ubiquitination, and degradation. The HIF-1 heterodimer binds to hypoxia response 
elements containing recognition sequence 5_-RCGTG-3_ and recruits coactivator molecules resulting in increased transcription initiation complex formation. mRNA 
synthesis production and translation of proteins to mediate physiologic responses to hypoxia. TF = transcription factors.
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hypoxia over the longer term on cardiac output (CO = HR × SV), 
ventilatory rate, as well as hematocrit and cellular oxygen 
demand/consumption may limit the negative influence of 
hypoxia. Ventilatory control is achieved via peripheral and central 
chemoreceptors. The effect of hypoxia on hematocrit is mediated 
via renal erythropoietin regulation.
The cellular adaptive response to hypoxia is regulated via the 
hypoxia-inducible factor (HIF) family of transcription factors 
(19). HIF-1 is a heterodimeric protein comprising an oxygen-
regulated subunit HIF-1 alpha and constitutively expressed HIF-1 
beta subunit (aryl hydrocarbon receptor nuclear translocator) 
(20) (Figure 3). Under normoxic conditions, HIF-1 alpha is rap-
idly removed by polyubiquitylation and proteasome degradation. 
Under hypoxic conditions, specific enzyme activity is reduced, 
intracellular HIF-1 alpha accumulates and translocates to the 
nucleus. Subsequent dimerization with HIF-1 beta and binding 
to coactivators result in transcriptional activation of hypoxia-
responsive genes involved in metabolism, cellular proliferation, 
vascular physiology, and erythropoiesis (Figure 4).
CLINICAL STUDIES OF OXYGEN 
THERAPY
The principle region of interest for studies of SpO2 in human 
clinical studies is the effect within normoxia (≥94%) and 
clinical cyanosis (85%). This region of interest oxygen saturation 
(85–94%) would not generally be considered symptomatic during 
health and could still be associated with adequate mitochondrial 
oxygenation, and so the benefits and harms of supplementing 
oxygen within this range during disease are of interest.
Clinical Studies in Adults
There is physiological first principle evidence that low oxygen 
increases respiratory rate; however, supplemental oxygen as a 
therapy to provide symptomatic relief of dyspnea in adults is 
ineffective (22). A Cochrane review of oxygen supplementation 
in adults with respiratory disease demonstrates the lack of good 
quality evidence (23).
Clinical Studies in Children
In children, the sensitivity of the developing brain to hypoxemia 
is much debated, yet has limited supporting evidence of benefits 
or risks in the region of interests (85–94% SpO2) (24). Hypoxemia 
is common in children who are unwell (25), in particular those 
with respiratory illness (26) and may often be undetected (27). 
The effects of hypoxia associated with newborn Hypoxic Ischemic 
Encephalopathy or out of hospital cardiac arrest are well described. 
Typically, such events are associated with a profound period 
of hypoxia often with marked acidosis and diminished cardiac 
output – though the ability of the young brain to withstand some 
episodes of prolonged hypoxemia can be impressive. Persisting 
hypoxia leads ultimately to cellular energy failure and cell death 
as the adapted mechanisms demonstrated above begin to fail. The 
boundary between hypoxemia and anoxia is termed dysoxia (28).
FIGURE 4 | Cellular consequences of hypoxia – Oxygen in children what level. Cellular consequences of hypoxia—adapted from Semenza (20) and Span 
and Bussink (21). As partial pressure of cellular O2 falls, there are a number of target genes involved in oxygen homestasis. Hypoxia-inducible factor-1-regulated 
genes include the 11 glycolytic enzymes aldolase A, aldolase C, enolase1, glyceraldehyde-3-phosphate dehydrogenase, hexokinase 1, hexokinase 2, lactate 
dehydrogenase A, phosphofructokinase L, phosphoglycerate. kinase 1, pyruvate kinase M, and triosephosphate isomerase. Abbreviations: EPO, erythropoietin; HO, 
heme oxygenase; IGF, insulin-like growth factor; IGFBP, IGF binding protein; NOS, nitric oxide synthase; PAI, plasminogen activator inhibitor; TGF, transforming 
growth factor; VEGF, vascular endothelial growth factor. 1 mmHg = 0.13 kPa, 10 mmHg = 1.3 kPa, 15 mmHg = 2 kPa.
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There is sufficient evidence (as above) to identify from 
physiological and biochemical principles that those who have 
cardiorespiratory or biochemical instability are most likely to be 
hypoxically challenged at a cellular level. Patients include those 
with significant acidosis associated with sepsis, dehydration, or 
diabetic ketoacidosis or those with a high probability of acute 
sudden reductions in global oxygen delivery, i.e., acute severe 
asthma or pneumothorax. In such patients, supplementing oxy-
gen to normoxic values provides a reliable buffer against shifts 
in the oxygen dissociation curve or sudden challenges to oxygen 
delivery.
From a clinical perspective, the more challenging questions 
are based around the clinical management of patients who 
are biochemically stable (or with only mild pyrexia/increased 
carbon dioxide) and have hypoxemia within the range 85–94%, 
particularly over the longer term of days, weeks, or months. These 
include children recovering from acute lower respiratory tract 
infection or chronic lung disease.
Chronic Oxygen Supplementation  
(Weeks or Months)
Preterm infants with lung disease often have hypoxemia and are 
provided with supplemental oxygen as a treatment. The early 
unrestricted use of oxygen for preterm infants in the 1950s was 
associated with a disastrous increase in the incidence of retin-
opathy of prematurity (29). The subsequent rebound restriction 
of supplemental oxygen reduced the incidence of ROP, but corre-
spondingly increased death and brain injury (30, 31). In the 1970s 
and 1980s, the development and use of transcutaneous oxygen 
sensors enabled oxygen to be better titrated, controlling the risk 
of supplementing oxygen. Though ROP continued to be prob-
lematic even within transcutaneous oxygen target ranges (32). 
More recent studies in preterm infants have considered the risks 
and benefits of different target ranges for oxygen saturation. In a 
pre-planned international meta-analysis, a study was closed early 
when it became apparent that there were excess deaths in those 
infants managed within a lower oxygen saturation range (33). Of 
significant note was that the difference in the peak median oxygen 
saturation separating the two groups was just 3% SpO2; 89% in the 
lower and 92% in the higher range. In this vulnerable population 
of preterm infants, small differences in oxygen saturation over 
prolonged periods of time within the range interest (85–94% 
SpO2) has important effects on outcomes.
Children beyond the newborn period may also be consid-
ered a vulnerable population. The most studied population in 
this age group is children with obstructive sleep apnea (OSA). 
Children with reported OSA attain lower high school scores 
than contemporary peers without reported OSA (34, 35). When 
6Langley and Cunningham Oxygen – When to Supplement?
Frontiers in Pediatrics | www.frontiersin.org January 2017 | Volume 4 | Article 138
tested in a randomized controlled trial however, the anticipated 
effect on learning was not identified (36), creating further debate 
(37), though recent studies continue to suggest that prolonged 
repeated episode of airway obstruction (and possibly the associ-
ated hypoxia) do have cognitive effects in developing brains (37). 
Random repeated episodic obstructive events over many months 
result in both sleep architecture arousals and recurrent hypox-
emic events; teasing out which is most associated with potential 
cognitive deficits is difficult.
Acute Oxygen Supplementation in 
Respiratory Disease
Is it helpful to have a one size fits for oxygen saturation limits? 
Should our response to oxygen saturation be more responsive and 
intuitive to the patients’ illness and symptoms? As one of the most 
commonly prescribed treatments, oxygen supplementation and 
its effects on illness is poorly studied.
In general, there is very little evidence, of poor quality, sup-
porting the use of oxygen in children with acute lower respiratory 
tract infection (38). Acute LRTI is the leading cause of mortality 
among children in developing countries and is responsible for 
up to 30% of all mortality in children under 5 years of age (39), 
with an estimated 120 million cases of pneumonia each year (40).
Hypoxemia is common in children with LRTI (41) and SpO2 
<94% is present in 73% of children under one year of age admitted 
to hospital in a developed setting with acute bronchiolitis (42). In 
older children with pneumonia in a developing healthcare set-
ting, hypoxemia (SpO2 <90%) is present in 13% (25). Outcomes 
are poorer in those with nutritional deficit at the time of hypoxia 
(43). The World Health Organization recommends an oxygen 
saturation target of 90% for supplementing oxygen in stable chil-
dren (44). This is generally considered a pragmatic proposal in 
resource poor countries where oxygen provision is challenging, 
but also takes account of the stability of the oxygen dissociation 
curve at oxygen saturation greater than 90%. In high and mid-
dle income healthcare settings, oxygen is generally provided to 
maintain oxygen saturation above 92%.
In a pilot trial for children with pneumonia, early use of 
supplemental oxygen did not prevent subsequent development 
of hypoxaemial (45). Children with pneumonia, provided with 
supplemental oxygen to maintain SpO2 ≥90% had fewer deaths 
than those who did not receive supplemental oxygen (46).
There is just one randomized controlled trial of oxygen supple-
mentation in acute respiratory disease in children. Bronchiolitis 
is the most common lower respiratory tract infection in children 
under one year of age. Most commonly caused by Respiratory 
Syncytial Virus the only effective management is maintenance of 
hydration and relief of hypoxemia. In 2005, a discrepancy arose 
between two guidelines for the management of bronchiolitis. 
With no evidence to support either position, a UK guideline rec-
ommending supplementing oxygen until normoxia was achieved 
(SpO2 ≥94%) and a US guideline recommended, on the basis of 
oxygen dissociation characteristics, that oxygen supplementation 
could be limited to <90% if the child was stable and improving. In 
a double-blind randomized controlled equivalence trial testing, 
these two oxygen saturation targets, outcomes for key clinical 
parameters were equivalent or possibly better for infants managed 
to the lower oxygen saturation target (42). Neurodevelopmental 
outcomes were not assessed within this trial, as the brief and 
improving oxygen saturation of trial subjects was not considered 
to be sufficient of neurodevelopmental concern—though this 
position is not accepted by all (47).
So do we know the correct target for oxygen saturation in 
acute lower respiratory tract infection in children? And what is 
it worth to know? In developed economies, there may be little 
appetite to push boundaries where outcomes are generally good 
and significant risk of severe neurodisability or death would be 
unacceptable outcomes (48). But just as early use of oxygen dem-
onstrated harm as well as good, so possibly is the case with use of 
supplemental oxygen in children. In the Bronchiolitis of Infancy 
Discharge Study, outcomes appeared better in those managed to 
a lower oxygen saturation (and so fewer received supplemental 
oxygen for a shorter duration) with more speedy recovery (from 
a parent perspective) and a faster ability to regain feeding. 
Oxygen toxicity was postulated as possible for these effects (42). 
In developing healthcare, the ability to most effectively distribute 
scarce supplemental oxygen as a resource does support further 
evaluation of target oxygen saturation. These are proposed to be 
tested in an MRC trial in Africa (the COAST trial).
Do we know the level at which we should supplement oxygen? 
Not yet.
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